Molecular Imaging and Biology

, Volume 17, Issue 2, pp 185–194 | Cite as

Optimization of Mesenchymal Stem Cells (MSCs) Delivery Dose and Route in Mice with Acute Liver Injury by Bioluminescence Imaging

  • Zhengran Li
  • Xiaojun Hu
  • Junjie Mao
  • Xuelian Liu
  • Lina Zhang
  • Jingjing Liu
  • Dan Li
  • Hong Shan
Research Article



Both experimental and initial clinical studies have shown the therapeutic potential of mesenchymal stem cells (MSCs) in liver disease. Noninvasive tracking of MSCs could facilitate its clinical translation. The purpose of this study was to optimize MSCs delivery dose and route in mice with acute liver injury using bioluminescence imaging (BLI) to track the cells.


MSCs were labeled with the Luc2-mKate2 dual-fusion reporter gene (MSCs-R). The fate of MSCs-R was tracked through in vivo BLI after administration of different doses or delivery through different routes.


When delivered via the superior mesenteric vein (SMV), the high-dose (1.0 × 106 and 5.0 × 105) group mice demonstrated high liver BLI signal but also had lethal portal vein embolization (PVE). By contrast, no PVE and its related death occurred in the low-dose (2.5 × 105) group mice. Thus, 2.5 × 105 is the optimal delivery dose. Three delivery routes, i.e., inferior vena cava (IVC), SMV, and intrahepatic (IH) injection, were also systematically compared. After IVC infusion, MSCs-R were quickly trapped inside the lungs, and no detectable homing to the liver and other organs was observed. By IH injection, lung entrapment was bypassed, but MSCs-R distribution was only localized in the injection region of the liver. By contrast, after SMV infusion, MSCs-R were dispersedly distributed and stayed as long as 7-day posttransplantation in the liver. The in vivo imaging results were further validated by ex vivo imaging, digital subtraction angiography (DSA), and tissue analysis. Therefore, SMV is the optimal MSCs delivery route for liver disease.


Collectively, BLI, which could dynamically and quantitatively track cellular location and survival, is useful in determining MSCs transplantation parameters.

Key words

Mesenchymal stem cells Liver disease Delivery dose Delivery route Bioluminescence imaging 



This work was supported by the National Natural Science Foundation of China (No. U1032002, 81271621, 81301266, 81101096) and Key Clinical Research Project of Public Health Ministry of China 2010–2012 (No. 164).

Conflict of Interest

The authors have declared that they have no conflict of interest.

Supplementary material

11307_2014_792_MOESM1_ESM.pdf (2.8 mb)
ESM 1 (PDF 2823 kb)


  1. 1.
    da Silva ML, Chagastelles PC, Nardi NB (2006) Mesenchymal stem cells reside in virtually all post-natal organs and tissues. J Cell Sci 119:2204–2213CrossRefGoogle Scholar
  2. 2.
    Lee KD, Kuo TK, Whang-Peng J et al (2004) In vitro hepatic differentiation of human mesenchymal stem cells. Hepatology 40:1275–1284CrossRefPubMedGoogle Scholar
  3. 3.
    Snykers S, Vanhaecke T, Papeleu P et al (2006) Sequential exposure to cytokines reflecting embryogenesis: the key for in vitro differentiation of adult bone marrow stem cells into functional hepatocyte-like cells. Toxicol Sci 94:330–341, discussion 235–339CrossRefPubMedGoogle Scholar
  4. 4.
    Banas A, Teratani T, Yamamoto Y et al (2007) Adipose tissue-derived mesenchymal stem cells as a source of human hepatocytes. Hepatology 46:219–228CrossRefPubMedGoogle Scholar
  5. 5.
    Chivu M, Dima SO, Stancu CI et al (2009) In vitro hepatic differentiation of human bone marrow mesenchymal stem cells under differential exposure to liver-specific factors. Transl Res 154:122–132CrossRefPubMedGoogle Scholar
  6. 6.
    Yamazaki S, Miki K, Hasegawa K et al (2003) Sera from liver failure patients and a demethylating agent stimulate transdifferentiation of murine bone marrow cells into hepatocytes in coculture with nonparenchymal liver cells. J Hepatol 39:17–23CrossRefPubMedGoogle Scholar
  7. 7.
    Qihao Z, Xigu C, Guanghui C, Weiwei Z (2007) Spheroid formation and differentiation into hepatocyte-like cells of rat mesenchymal stem cell induced by co-culture with liver cells. DNA Cell Biol 26:497–503CrossRefPubMedGoogle Scholar
  8. 8.
    Deng X, Chen YX, Zhang X et al (2008) Hepatic stellate cells modulate the differentiation of bone marrow mesenchymal stem cells into hepatocyte-like cells. J Cell Physiol 217:138–144CrossRefPubMedGoogle Scholar
  9. 9.
    Kazemnejad S, Allameh A, Soleimani M et al (2009) Biochemical and molecular characterization of hepatocyte-like cells derived from human bone marrow mesenchymal stem cells on a novel three-dimensional biocompatible nanofibrous scaffold. J Gastroenterol Hepatol 24:278–287CrossRefPubMedGoogle Scholar
  10. 10.
    Ji R, Zhang N, You N et al (2012) The differentiation of MSCs into functional hepatocyte-like cells in a liver biomatrix scaffold and their transplantation into liver-fibrotic mice. Biomaterials 33:8995–9008CrossRefPubMedGoogle Scholar
  11. 11.
    Ishii K, Yoshida Y, Akechi Y et al (2008) Hepatic differentiation of human bone marrow-derived mesenchymal stem cells by tetracycline-regulated hepatocyte nuclear factor 3beta. Hepatology 48:597–606CrossRefPubMedGoogle Scholar
  12. 12.
    Sato Y, Araki H, Kato J et al (2005) Human mesenchymal stem cells xenografted directly to rat liver are differentiated into human hepatocytes without fusion. Blood 106:756–763CrossRefPubMedGoogle Scholar
  13. 13.
    Kuo TK, Hung SP, Chuang CH, et al. (2008) Stem cell therapy for liver disease: parameters governing the success of using bone marrow mesenchymal stem cells. Gastroenterology 134: 2111–2121, 2121 e2111-2113.Google Scholar
  14. 14.
    Di Rocco G, Gentile A, Antonini A et al (2012) Analysis of biodistribution and engraftment into the liver of genetically modified mesenchymal stromal cells derived from adipose tissue. Cell Transplant 21:1997–2008CrossRefPubMedGoogle Scholar
  15. 15.
    Parekkadan B, van Poll D, Suganuma K et al (2007) Mesenchymal stem cell-derived molecules reverse fulminant hepatic failure. PLoS One 2:e941CrossRefPubMedCentralPubMedGoogle Scholar
  16. 16.
    Banas A, Teratani T, Yamamoto Y et al (2008) IFATS collection: in vivo therapeutic potential of human adipose tissue mesenchymal stem cells after transplantation into mice with liver injury. Stem Cells 26:2705–2712CrossRefPubMedGoogle Scholar
  17. 17.
    van Poll D, Parekkadan B, Cho CH et al (2008) Mesenchymal stem cell-derived molecules directly modulate hepatocellular death and regeneration in vitro and in vivo. Hepatology 47:1634–1643CrossRefPubMedGoogle Scholar
  18. 18.
    Kharaziha P, Hellstrom PM, Noorinayer B et al (2009) Improvement of liver function in liver cirrhosis patients after autologous mesenchymal stem cell injection: a phase I-II clinical trial. Eur J Gastroenterol Hepatol 21:1199–1205CrossRefPubMedGoogle Scholar
  19. 19.
    Peng L, Xie DY, Lin BL et al (2011) Autologous bone marrow mesenchymal stem cell transplantation in liver failure patients caused by hepatitis B: short-term and long-term outcomes. Hepatology 54:820–828CrossRefPubMedGoogle Scholar
  20. 20.
    Zhou B, Shan H, Li D et al (2010) MR tracking of magnetically labeled mesenchymal stem cells in rats with liver fibrosis. Magn Reson Imaging 28:394–399CrossRefPubMedGoogle Scholar
  21. 21.
    Yukawa H, Watanabe M, Kaji N et al (2012) Monitoring transplanted adipose tissue-derived stem cells combined with heparin in the liver by fluorescence imaging using quantum dots. Biomaterials 33:2177–2186CrossRefPubMedGoogle Scholar
  22. 22.
    Gholamrezanezhad A, Mirpour S, Bagheri M et al (2011) In vivo tracking of 111In-oxine labeled mesenchymal stem cells following infusion in patients with advanced cirrhosis. Nucl Med Biol 38:961–967CrossRefPubMedGoogle Scholar
  23. 23.
    Wu C, Li J, Pang P et al (2014) Polymeric vector-mediated gene transfection of MSCs for dual bioluminescent and MRI tracking in vivo. Biomaterials 35:8249–8260CrossRefPubMedGoogle Scholar
  24. 24.
    Mori T, Kiyono T, Imabayashi H et al (2005) Combination of hTERT and bmi-1, E6, or E7 induces prolongation of the life span of bone marrow stromal cells from an elderly donor without affecting their neurogenic potential. Mol Cell Biol 25:5183–5195CrossRefPubMedCentralPubMedGoogle Scholar
  25. 25.
    Zhang B, Shan H, Li D et al (2012) The inhibitory effect of MSCs expressing TRAIL as a cellular delivery vehicle in combination with cisplatin on hepatocellular carcinoma. Cancer Biol Ther 13:1175–1184CrossRefPubMedCentralPubMedGoogle Scholar
  26. 26.
    Li D, Liu S, Liu R et al (2013) Targeting the EphB4 receptor for cancer diagnosis and therapy monitoring. Mol Pharm 10:329–336CrossRefPubMedCentralPubMedGoogle Scholar
  27. 27.
    Liu S, Li D, Park R et al (2013) PET imaging of colorectal and breast cancer by targeting EphB4 receptor with 64Cu-labeled hAb47 and hAb131 antibodies. J Nucl Med 54:1094–1100CrossRefPubMedGoogle Scholar
  28. 28.
    Li D, Liu S, Liu R et al (2014) Axl-targeted cancer imaging with humanized antibody h173. Mol Imaging Biol 16:511–518CrossRefPubMedGoogle Scholar
  29. 29.
    Gu E, Chen WY, Gu J et al (2012) Molecular imaging of stem cells: tracking survival, biodistribution, tumorigenicity, and immunogenicity. Theranostics 2:335–345CrossRefPubMedCentralPubMedGoogle Scholar
  30. 30.
    Nguyen PK, Riegler J, Wu JC (2014) Stem cell imaging: from bench to bedside. Cell Stem Cell 14:431–444CrossRefPubMedGoogle Scholar
  31. 31.
    Shcherbo D, Murphy CS, Ermakova GV et al (2009) Far-red fluorescent tags for protein imaging in living tissues. Biochem J 418:567–574CrossRefPubMedCentralPubMedGoogle Scholar
  32. 32.
    Lee RH, Seo MJ, Pulin AA et al (2009) The CD34-like protein PODXL and alpha6-integrin (CD49f) identify early progenitor MSCs with increased clonogenicity and migration to infarcted heart in mice. Blood 113:816–826CrossRefPubMedCentralPubMedGoogle Scholar
  33. 33.
    Yukawa H, Noguchi H, Oishi K et al (2009) Cell transplantation of adipose tissue-derived stem cells in combination with heparin attenuated acute liver failure in mice. Cell Transplant 18:611–618PubMedGoogle Scholar
  34. 34.
    Manibusan MK, Odin M, Eastmond DA (2007) Postulated carbon tetrachloride mode of action: a review. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev 25:185–209CrossRefPubMedGoogle Scholar
  35. 35.
    Gao J, Dennis JE, Muzic RF et al (2001) The dynamic in vivo distribution of bone marrow-derived mesenchymal stem cells after infusion. Cells Tissues Organs 169:12–20CrossRefPubMedGoogle Scholar
  36. 36.
    Schrepfer S, Deuse T, Reichenspurner H et al (2007) Stem cell transplantation: the lung barrier. Transplant Proc 39:573–576CrossRefPubMedGoogle Scholar
  37. 37.
    Fischer UM, Harting MT, Jimenez F et al (2009) Pulmonary passage is a major obstacle for intravenous stem cell delivery: the pulmonary first-pass effect. Stem Cells Dev 18:683–692CrossRefPubMedCentralPubMedGoogle Scholar
  38. 38.
    Deak E, Ruster B, Keller L et al (2010) Suspension medium influences interaction of mesenchymal stromal cells with endothelium and pulmonary toxicity after transplantation in mice. Cytotherapy 12:260–264CrossRefPubMedGoogle Scholar
  39. 39.
    Kerkela E, Hakkarainen T, Makela T et al (2013) Transient proteolytic modification of mesenchymal stromal cells increases lung clearance rate and targeting to injured tissue. Stem Cells Transl Med 2:510–520CrossRefPubMedCentralPubMedGoogle Scholar
  40. 40.
    Gregory CA, Ylostalo J, Prockop DJ (2005) Adult bone marrow stem/progenitor cells (MSCs) are preconditioned by microenvironmental “niches” in culture: a two-stage hypothesis for regulation of MSC fate. Sci STKE 2005:pe37Google Scholar
  41. 41.
    Breitbach M, Bostani T, Roell W et al (2007) Potential risks of bone marrow cell transplantation into infarcted hearts. Blood 110:1362–1369CrossRefPubMedGoogle Scholar
  42. 42.
    am Esch JS 2nd, Knoefel WT, Klein M et al (2005) Portal application of autologous CD133+ bone marrow cells to the liver: a novel concept to support hepatic regeneration. Stem Cells 23:463–470CrossRefGoogle Scholar
  43. 43.
    Lee RH, Pulin AA, Seo MJ et al (2009) Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-inflammatory protein TSG-6. Cell Stem Cell 5:54–63CrossRefPubMedCentralPubMedGoogle Scholar
  44. 44.
    Ishizaka S, Horie N, Satoh K et al (2013) Intra-arterial cell transplantation provides timing-dependent cell distribution and functional recovery after stroke. Stroke 44:720–726CrossRefPubMedGoogle Scholar
  45. 45.
    Huang Z, Shen Y, Pei N et al (2013) The effect of nonuniform magnetic targeting of intracoronary-delivering mesenchymal stem cells on coronary embolisation. Biomaterials 34:9905–9916CrossRefPubMedGoogle Scholar
  46. 46.
    Cai J, Yu X, Xu R et al (2014) Maximum efficacy of mesenchymal stem cells in rat model of renal ischemia-reperfusion injury: renal artery administration with optimal numbers. PLoS One 9:e92347CrossRefPubMedCentralPubMedGoogle Scholar
  47. 47.
    Khan AA, Parveen N, Mahaboob VS et al (2008) Safety and efficacy of autologous bone marrow stem cell transplantation through hepatic artery for the treatment of chronic liver failure: a preliminary study. Transplant Proc 40:1140–1144CrossRefPubMedGoogle Scholar
  48. 48.
    Harichandan A, Buhring HJ (2011) Prospective isolation of human MSC. Best Pract Res Clin Haematol 24:25–36CrossRefPubMedGoogle Scholar
  49. 49.
    Meier RP, Muller YD, Morel P et al (2013) Transplantation of mesenchymal stem cells for the treatment of liver diseases, is there enough evidence? Stem Cell Res 11:1348–1364CrossRefPubMedGoogle Scholar
  50. 50.
    Spaggiari GM, Capobianco A, Becchetti S et al (2006) Mesenchymal stem cell-natural killer cell interactions: evidence that activated NK cells are capable of killing MSCs, whereas MSCs can inhibit IL-2-induced NK-cell proliferation. Blood 107:1484–1490CrossRefPubMedGoogle Scholar
  51. 51.
    Eliopoulos N, Stagg J, Lejeune L et al (2005) Allogeneic marrow stromal cells are immune rejected by MHC class I- and class II-mismatched recipient mice. Blood 106:4057–4065CrossRefPubMedGoogle Scholar
  52. 52.
    Zangi L, Margalit R, Reich-Zeliger S et al (2009) Direct imaging of immune rejection and memory induction by allogeneic mesenchymal stromal cells. Stem Cells 27:2865–2874CrossRefPubMedGoogle Scholar
  53. 53.
    Grinnemo KH, Mansson A, Dellgren G et al (2004) Xenoreactivity and engraftment of human mesenchymal stem cells transplanted into infarcted rat myocardium. J Thorac Cardiovasc Surg 127:1293–1300CrossRefPubMedGoogle Scholar
  54. 54.
    Coyne TM, Marcus AJ, Woodbury D, Black IB (2006) Marrow stromal cells transplanted to the adult brain are rejected by an inflammatory response and transfer donor labels to host neurons and glia. Stem Cells 24:2483–2492CrossRefPubMedGoogle Scholar
  55. 55.
    Poncelet AJ, Vercruysse J, Saliez A, Gianello P (2007) Although pig allogeneic mesenchymal stem cells are not immunogenic in vitro, intracardiac injection elicits an immune response in vivo. Transplantation 83:783–790CrossRefPubMedGoogle Scholar
  56. 56.
    Bertolino P, Klimpel G, Lemon SM (2000) Hepatic inflammation and immunity: a summary of a conference on the function of the immune system within the liver. Hepatology 31:1374–1378CrossRefPubMedGoogle Scholar
  57. 57.
    Mehal WZ, Azzaroli F, Crispe IN (2001) Immunology of the healthy liver: old questions and new insights. Gastroenterology 120:250–260CrossRefPubMedGoogle Scholar

Copyright information

© World Molecular Imaging Society 2014

Authors and Affiliations

  • Zhengran Li
    • 1
  • Xiaojun Hu
    • 1
  • Junjie Mao
    • 1
  • Xuelian Liu
    • 1
  • Lina Zhang
    • 1
  • Jingjing Liu
    • 1
  • Dan Li
    • 1
  • Hong Shan
    • 1
    • 2
  1. 1.Department of RadiologyThe Third Affiliated Hospital of Sun Yat-sen UniversityGuangzhouChina
  2. 2.Interventional Radiology InstituteSun Yat-sen UniversityGuangzhouChina

Personalised recommendations